Binds Virus Or Component Thereof Patents (Class 424/147.1)
-
Patent number: 6673355Abstract: The rotavirus nonstructural glycoprotein, NSP4, performs multiple functions in the virus replication cycle, especially during viral morphogenesis. Specifically, NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope during the budding of newly formed subviral particles into the endoplasmic reticulum (ER). The present invention relates to NSP4 and methods of use. More particulary, it relates to the use of NSP4 and fragments thereof (NSP4 114-135, NSP4 120-147, NSP4 112-174, or NSP4 112-150) as a prevention and/or treatment of rotaviral disease.Type: GrantFiled: November 3, 2000Date of Patent: January 6, 2004Assignee: Baylor College of MedicineInventors: Mary K. Estes, Judith M. Ball, Peng Tian
-
Patent number: 6656467Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: GrantFiled: January 26, 2001Date of Patent: December 2, 2003Assignees: MedImmune, Inc., Applied Molecular EvolutionInventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20030206907Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: ApplicationFiled: April 9, 2003Publication date: November 6, 2003Inventor: Scott Koenig
-
Patent number: 6627196Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.Type: GrantFiled: August 25, 2000Date of Patent: September 30, 2003Assignee: Genentech, Inc.Inventors: Sharon A. Baughman, Steven Shak
-
Patent number: 6620412Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: GrantFiled: September 16, 2002Date of Patent: September 16, 2003Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20030165507Abstract: Human monoclonal rabies virus neutralizing antibodies represent a safe and efficacious post-exposure prophylactic therapy for individuals exposed to a rabies virus. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, is described.Type: ApplicationFiled: May 4, 2001Publication date: September 4, 2003Inventors: Douglas C. Hooper, Bernhard Dietzschold
-
Patent number: 6613563Abstract: The present invention relates to gene therapy. In particular, therapeutic agents, therapeutic gene products, and compositions are disclosed. Various systems and methods useful in targeting and delivering non-native nucleotide sequences to specific cells are disclosed, wherein virus-antibody-ligand conjugates are used to facilitate targeting and delivery.Type: GrantFiled: March 13, 1998Date of Patent: September 2, 2003Assignees: Selective Gentics, Inc., UAB Research FoundationInventors: Barbara A. Sosnowski, Andrew Baird, Glenn F. Pierce, David T. Curiel, Joanne T. Douglas, Buck E. Rogers
-
Publication number: 20030157579Abstract: The current invention provides methods and systems for detecting the presence of a target molecule either in vitro or in vivo. The systems of the invention comprise interacting components, a reporter and a low-affinity inhibitor of the reporter, each of which is fused to a member of a binding pair. A target molecule that interferes with binding of the binding pair members can therefore be identified by detecting activation of the reporter molecule.Type: ApplicationFiled: February 14, 2002Publication date: August 21, 2003Applicant: KaloBios, Inc.Inventors: Robert F. Balint, Jen-Horng Her
-
Patent number: 6596478Abstract: The present invention comprises methods, devices and compositions for detection of endogenous retroviruses found in xenotransplant materials. The methods and compositions are suited for detection of endogenous type-C retroviruses and in particular, for porcine endogenous retrovirus, PERV.Type: GrantFiled: March 12, 2001Date of Patent: July 22, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Walid M. Heneine, William M. Switzer, Paul A. Sandstrom, Aprille L. Matthews, Thomas M. Folks
-
Publication number: 20030099634Abstract: Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.Type: ApplicationFiled: April 22, 2002Publication date: May 29, 2003Inventors: Maria A. Vitiello, Robert W. Chesnut, Alessandro D. Sette, Esteban Celis, Howard Grey
-
Patent number: 6565849Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: GrantFiled: March 2, 2001Date of Patent: May 20, 2003Assignee: MedImmune, Inc.Inventor: Scott Koenig
-
Patent number: 6562341Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: August 30, 2001Date of Patent: May 13, 2003Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6558961Abstract: Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the individual are provided.Type: GrantFiled: September 3, 1999Date of Patent: May 6, 2003Assignee: PowderJect Research LimitedInventors: David F. Sarphie, Lee K. Roberts, Deborah L. Fuller
-
Publication number: 20030082186Abstract: The present invention relates generally to the field of virology. More particularly, the invention relates to the discovery that peptides, which bind to the Hepatitis B virus (HBV) core and e antigens, can be used to inhibit HBV infection. Embodiments concern “binding partners”, which include peptides, peptidomimetics, and chemicals that resemble these molecules that interact with HBV core and e antigens, biological complexes having HBV core and e antigens joined to said binding partners, methods of identifying such binding partners, pharmaceuticals having binding partners, and methods of treatments and prevention of HBV infection.Type: ApplicationFiled: May 21, 2002Publication date: May 1, 2003Inventor: Matti Sallberg
-
Publication number: 20030082185Abstract: This invention provides a composition which comprises an admixture of two compounds, wherein one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherein the relative mass ratio of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the above composition effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.Type: ApplicationFiled: January 28, 2000Publication date: May 1, 2003Inventors: William C. Olson, Paul J. Maddon
-
Patent number: 6537809Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro primary of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein ≦2×10−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.Type: GrantFiled: December 20, 2000Date of Patent: March 25, 2003Assignee: Xenerex BiosciencesInventors: Peter Brams, Phillip R. Morrow
-
Patent number: 6538114Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.Type: GrantFiled: April 19, 1996Date of Patent: March 25, 2003Assignee: Karolina Innovations ABInventors: Mats Axel Atterdag Persson, Tobias Erik Allander
-
Patent number: 6531127Abstract: The invention relates to seroreactive regions on the E1 and E2 proteins of human papillomavirus 16 (HPV 16). The invention also relates to a vaccine that contains peptides comprising at least one seroreactive region of the E1 and/or E2 proteins. The invention likewise embraces compositions for diagnostic purposes, which contain peptides with the seroreactive regions. Further, the invention relates to antibodies that bind to seroreactive regions of the E1 and/or E2 proteins of HPV 16, and compositions comprising such antibodies, which can be used for diagnostic purposes.Type: GrantFiled: January 12, 2001Date of Patent: March 11, 2003Assignee: Dade Behring Marburg GmbHInventors: Martin Müller, Lutz Gissmann
-
Patent number: 6528056Abstract: A method of inhibiting viral infection using a monovalent antigen binding protein comprising a single domain binding unit capable of binding to a virus is described. Preferably the protein is a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains. Food, pharmaceutical and cosmetic products comprising such proteins are also described together with a method for selecting inhibiting proteins from a large population of mainly containing non-inhibiting, but infectious agent binding fragments.Type: GrantFiled: April 21, 2000Date of Patent: March 4, 2003Assignee: Unilever Patent Holdings B.V.Inventors: Sandra Bezemer, Leon Gerardus Joseph Frenken, Johannes Joseph Wilhelmus deHaard, Adrianus Marinus Ledeboer, Cornelis Theodorus Verrips
-
Patent number: 6521403Abstract: Antibodies to two new epitopes on the HCV envelope proteins we, identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.Type: GrantFiled: August 24, 2000Date of Patent: February 18, 2003Assignee: Innogenetics N.V.Inventors: Geert Maertens, Erik Depla, Marie-Ange Buyse
-
Publication number: 20030022226Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: ApplicationFiled: September 16, 2002Publication date: January 30, 2003Inventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20030017448Abstract: A method for the prevention of intra uterine infection of fetuses with porcine reproductive and respiratory syndrome virus (PRRSV) is provided comprising administering to a pregnant female a composition containing an effective dose of anti-PRRSV antibodies. Also provided is a method for the prophylaxis or treatment of porcine reproductive and respiratory syndrome comprising administering to a pig a composition comprising an effective amount of anti-PRRS virus antibodies.Type: ApplicationFiled: February 22, 2002Publication date: January 23, 2003Applicant: The Board of Regents of the University of NebraskaInventor: Fernando A. Osorio
-
Publication number: 20030017156Abstract: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.Type: ApplicationFiled: May 9, 1995Publication date: January 23, 2003Inventors: AMY J. WEINER, MICHAEL HOUGHTON
-
Publication number: 20020177126Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: November 28, 2001Publication date: November 28, 2002Applicant: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Patent number: 6479641Abstract: Methods for detecting human parvovirus B19 in and removing it from biological samples such as blood are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human parvovirus B19 and/or B19-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.Type: GrantFiled: June 14, 2001Date of Patent: November 12, 2002Assignee: Dyax Corp.Inventor: E. Fayelle Whelihan
-
Publication number: 20020164326Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: January 26, 2001Publication date: November 7, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20020159993Abstract: The present invention provides for antibodies against nerous necrosis virus (NNV) and infectious pancreatic necrosis (IPNV) virus. The antibodies include polyclonal and monoclonal antibodies. NNV and IPNV are produced from an immortal cell line derived from Epinephelus coioides having an ATCC deposit number of PTA-859. The present invention also provides methods for detecting viral infections in fish using enzyme immunoassay (EIA).Type: ApplicationFiled: December 6, 2001Publication date: October 31, 2002Inventor: Shau-Chi Chi
-
Patent number: 6471962Abstract: Two monoclonal antibodies which neutralize all infectious bursal disease viruses are employed in the preparation of infectious bursal disease vaccines. A panel of monoclonal antibodies can be used to characterize the infectious bursal disease virus strains present, according to neutralization site characteristics.Type: GrantFiled: October 2, 1992Date of Patent: October 29, 2002Assignee: The University of MarylandInventor: David Snyder
-
Publication number: 20020155582Abstract: The present invention provides a replication competent hepatitis C virus that includes a heterologous polynucleotide present in the 3′ non-translated RNA. The invention also includes methods for modifying a hepatitis C virus, selecting a replication competent hepatitis C virus, detecting a replication competent hepatitis C virus, and identifying a compound that inhibits replication of a hepatitis C virus.Type: ApplicationFiled: December 23, 2000Publication date: October 24, 2002Inventors: Stanley M. Lemon, MinKyung Yi
-
Publication number: 20020150590Abstract: The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQ-VAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPIG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.Type: ApplicationFiled: August 1, 2001Publication date: October 17, 2002Applicant: The Council of the Queensland Institute of Medical Research, CSL LimitedInventors: Rajiv Khanna, Beverley Mavis Kerr, Ihor Stephan Misko, Denis James Moss, Scott Renton Burrows
-
Construction and characterization of monoclonal antibodies against western equine encephalitis virus
Publication number: 20020141997Abstract: Construction and characterization of mouse monoclonal antibodies against western equine encephalitis virus (WEE) for potential use in detection, diagnosis, and immunotherapy are disclosed. Antibodies were prepared from hybridoma cells and further characterized by ELISAs, Western blotting, isotyping, and immunoprecipitation. The antibodies were also tested for cross-reactivity to other alphaviruses, such as Sindbis virus (SIN), Venezuelan equine encephalitis virus (VEE), and eastern equine encephalitis (EEE). All antibodies bound to WEE antigen in ELISAs, whereas only a subgroup of antibodies was found to be active in Western blotting and immunoprecipitations. A subset of antibodies was found to cross-react with other alphaviruses, such as SIN, VEE, and EEE.Type: ApplicationFiled: February 27, 2001Publication date: October 3, 2002Applicant: The Minister of National DefenceInventor: Leslie P. Nagata -
Patent number: 6458933Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.Type: GrantFiled: May 19, 1999Date of Patent: October 1, 2002Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Patent number: 6451309Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: GrantFiled: February 9, 2001Date of Patent: September 17, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20020110561Abstract: A composition comprising:Type: ApplicationFiled: September 7, 2001Publication date: August 15, 2002Inventors: Dirk L. Teagarden, Nancy J. Britten, Scott A. Brown, James F. Caputo, Leslie C. Eaton, Ondrej Hendl, Syed F. Huda, Harry M. King, Susan M. Machkovech, Randal Lee Schapaugh, Stanley M. Speaker, Jean M. Steele, Ching-Chiang Su, Terry R. Urban, Niki A. Waldron, Monica L. Whitmire
-
Patent number: 6432632Abstract: A fluorescence polarization method for analyzing an assay-object in a sample is provided. The fluorescence polarization method includes the steps of: (a) providing a fluorescent-labeled protein in which a protein is covalently bound to a fluorochrome(s), wherein the protein is capable of specifically binding to the assay-object; (b) allowing the fluorescent-labeled protein to bind to the assay-object; and (c) measuring a change in the degree of fluorescence polarization which has taken place in the fluorescent-labeled protein by its binding to the assay-object.Type: GrantFiled: July 23, 1999Date of Patent: August 13, 2002Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Hiroshi Nakayama, Jinsei Miyazaki
-
Publication number: 20020106374Abstract: This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and (c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell.Type: ApplicationFiled: July 25, 2001Publication date: August 8, 2002Inventors: William C. Olson, Paul J. Maddon
-
Publication number: 20020098189Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: March 1, 2001Publication date: July 25, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20020086020Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: ApplicationFiled: January 10, 2002Publication date: July 4, 2002Applicant: OSEL, INC.Inventor: Peter P. Lee
-
Patent number: 6413771Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein≦2×10−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.Type: GrantFiled: June 18, 1999Date of Patent: July 2, 2002Assignee: IDEC Pharmaceuticals CorporationInventors: Peter Brams, Phillip R. Morrow
-
Publication number: 20020081295Abstract: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the treatment or prevention of human diseases, which involve the onset of B cell tolerance, such as chronic viral infection, chronic inflammatory disease, and neoplasia.Type: ApplicationFiled: April 13, 2001Publication date: June 27, 2002Inventors: John T. Schiller, Bryce Chackerian, Douglas R. Lowy
-
Patent number: 6406864Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSC is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.Type: GrantFiled: January 3, 2001Date of Patent: June 18, 2002Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Publication number: 20020058038Abstract: The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.Type: ApplicationFiled: March 19, 2001Publication date: May 16, 2002Inventor: Charles A. Nicolette
-
Publication number: 20020051787Abstract: Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.Type: ApplicationFiled: May 3, 2001Publication date: May 2, 2002Inventors: Gregory Prince, Leslie S. Johnson
-
Patent number: 6372214Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPSc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: April 13, 2000Date of Patent: April 16, 2002Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6365156Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: GrantFiled: April 14, 2000Date of Patent: April 2, 2002Assignee: Osel, Inc.Inventor: Peter P. Lee
-
Publication number: 20020018780Abstract: The present invention relates to a vaccine that comprises selected epitopes within the F protein structure that have been proven to specifically interact with known potent neutralizing antibodies while simultaneously being presented as part of a synthetic structure that offers these epitopes apart from the other non-neutralizing antigenic determinants of the virus but held in a native conformational form and thereby capable of eliciting neutralizing antibodies.Type: ApplicationFiled: May 25, 2001Publication date: February 14, 2002Inventors: Scott Koenig, Mark S. Hanson, JoAnn Suzich, Nancy Ulbrandt
-
Publication number: 20020009447Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: ApplicationFiled: February 9, 2001Publication date: January 24, 2002Inventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20020004046Abstract: Therapeutically effective anti-microbial compositions, useful especially against respiratory diseases caused or mediated by viruses, bacteria, and other respiratory parasites are disclosed, wherein said compositions comprise at least one neutralizing antibody, including high affinity antibodies, and an additional anti-infectious agent, such as an antiviral agent, for example, ribavirin, amantadine, rimantadine, or a neuraminidase-inhibitor. or anti-bacterial agents, including other antibodies. Also disclosed are methods of using such compositions to treat and/or prevent respiratory and related diseases.Type: ApplicationFiled: May 3, 2001Publication date: January 10, 2002Inventor: Leslie S. Johnson
-
Publication number: 20020001585Abstract: This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress.Type: ApplicationFiled: April 9, 2001Publication date: January 3, 2002Inventors: Jeffrey Browning, Maryann Puglielli, Rafi Ahmed
-
Patent number: 6322794Abstract: The invention relates to seroreactive epitopes on proteins of human papillomavirus HPV18. In addition, the invention relates to peptides which have amino-acid sequences which coincide in whole or in part with the sequences of the seroreactive epitopes, and to vaccines which contain such peptides.Type: GrantFiled: December 10, 1993Date of Patent: November 27, 2001Assignee: Dade Behring Marburg GmbHInventors: Conrad Bleul, Lutz Gissmann, Martin Müller